STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

Cancer Immunology, Immunotherapy

Volumn 64, Issue 8, 2015, Pages 1057-1066

  Wang, Zili ^a,b   Celis, Esteban ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

CD8 T cells; Immunotherapy; Peptide vaccines; STING; Type I interferon

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CD8 ANTIGEN; CYCLIC GMP; EPITOPE; INTERFERON; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; BIS(3',5')-CYCLIC DIGUANYLIC ACID; CANCER VACCINE; CD40 ANTIGEN; INTERFERON RECEPTOR; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MPYS PROTEIN, MOUSE; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; GENE; GENE ACTIVATION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; STIMULATOR OF INTERFERON GENE; SURVIVAL TIME; TREATMENT RESPONSE; VIRUS INFECTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; PROCEDURES; SKIN NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYCLIC GMP; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLY I-C; RECEPTORS, INTERFERON; SKIN NEOPLASMS; VACCINES, SUBUNIT;

EID: 84937978529     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1713-5     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–271
3. Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327
4. Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119–2127
5. Smith JW 2nd, Walker EB, Fox BA et al (2003) Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 21:1562–1573
6. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z (2006) Signals required for programming effector and memory development by CD8+ T cells. Immunological Rev 211:81–92
7. Horkheimer I, Quigley M, Zhu J, Huang X, Chao NJ, Yang Y (2009) Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation. Blood 113:5330–5339
8. Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF (2013) Type I interferon response and innate immune sensing of cancer. Trends Immunol 34:67–73
9. Schmeisser H, Fey SB, Horowitz J, Fischer ER, Balinsky CA, Miyake K, Bekisz J, Snow AL, Zoon KC (2013) Type I interferons induce autophagy in certain human cancer cell lines. Autophagy 9:683–696
10. Coit DG, Andtbacka R, Anker CJ et al (2013) Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:395–407
11. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE (2011) STING is a direct innate immune sensor of cyclic di-GMP. Nature 478:515–518
12. Parvatiyar K, Zhang Z, Teles RM et al (2012) The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol 13:1155–1161
13. Karaolis DK, Means TK, Yang D et al (2007) Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 178:2171–2181
14. McWhirter SM, Barbalat R, Monroe KM et al (2009) A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med 206:1899–1911
15. Shu C, Yi G, Watts T, Kao CC, Li P (2012) Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system. Nat Struct Mol Biol 19:722–724
16. Abe T, Barber GN (2014) Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. J Virol 88:5328–5341
17. Buteau C, Markovic SN, Celis E (2002) Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc 77:339–349
18. Cho HI, Celis E (2009) Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69:9012–9019
19. Barrios K, Celis E (2012) TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother 61:1307–1317
20. Cho HI, Reyes-Vargas E, Delgado JC, Celis E (2012) A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res 72:1986–1995
21. Cho HI, Barrios K, Lee YR, Linowski AK, Celis E (2013) BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother 62:787–799
22. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M (1994) Functional role of type I and type II interferons in antiviral defense. Science 264:1918–1921
23. Overwijk WW, Theoret MR, Finkelstein SE et al (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569–580
24. Cho HI, Lee YR, Celis E (2011) Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood 117:135–144
25. Fortier MH, Caron E, Hardy MP, Voisin G, Lemieux S, Perreault C, Thibault P (2008) The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med 205:595–610
26. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH (2004) New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103:2677–2682
27. Liu L, Chahroudi A, Silvestri G et al (2002) Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med 8:185–189
28. Jin L, Hill KK, Filak H, Mogan J, Knowles H, Zhang B, Perraud AL, Cambier JC, Lenz LL (2011) MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP. J Immunol 187:2595–2601
29. Becker JC, Andersen MH, Hofmeister-Muller V et al (2012) Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 61:2091–2103
30. Dangoor A, Lorigan P, Keilholz U et al (2010) Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother 59:863–873
31. Hinrichs CS, Rosenberg SA (2014) Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunological Rev 257:56–71
32. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174:4465–4469
33. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 169:350–358